Literature DB >> 3976473

Clinical and hemodynamic effects of combined propranolol and nifedipine therapy versus propranolol alone in patients with angina pectoris.

S Braun, R Terdiman, D Berenfeld, S Laniado.   

Abstract

To determine the comparative effectiveness and hemodynamic effects of long-term oral treatment with propranolol alone and combined with nifedipine in patients with stable angina pectoris, 20 patients with coronary disease were studied by equilibrium radionuclide ventriculography. Measurements were performed at rest and during supine bicycle exercise before treatment, after 4 weeks on propranolol, 1 hour after institution of combined propranolol and nifedipine treatment, and after 4 weeks on the combined treatment. The reduction in exercise rate-pressure product induced by the combination (17.2 +/- 2.6 X 10(3)) was significantly greater (p less than 0.001) than that attained by propranolol alone (19.3 +/- 2.8 X 10(3)). In patients at rest, neither propranolol nor the combined therapy altered global left ventricular (LV) ejection fraction (EF). Without drugs and on propranolol, exercise EF decreased significantly. On the combined therapy there was a significant improvement in exercise EF compared both with rest values (p less than 0.01) and with exercise EF on propranolol (p less than 0.001). Exercise tolerance, expressed as total work load, significantly increased on propranolol and further increased on combined therapy. Thus the combined propranolol/nifedipine therapy in patients with stable angina proved to be hemodynamically superior to therapy with propranolol alone and safe even in patients with moderately depressed LV function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3976473     DOI: 10.1016/0002-8703(85)90551-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  The combination of slow-release nifedipine and atenolol for stable angina.

Authors:  D G Waller; V F Challenor
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 3.  Beta-adrenoceptor antagonists plus nifedipine in the treatment of chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; C F George
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  The effects of felodipine in angina pectoris.

Authors:  A R Lorimer; P MacFarlane; S Pringle; M P Barbour; Y Fox; T D Lawrie
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  The effects of the novel anti-anginal compound RS 43285 on myocardial conduction in the anaesthetized dog.

Authors:  M C Allely; B J Alps
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

6.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.